Therapie最新文献

{"title":"Évaluation des dispositifs médicaux numériques : comment prendre en compte les spécificités de ces solutions ?","authors":"Anouk Trancart ,&nbsp;Valery-Pierre Riche ,&nbsp;Antoine Disset ,&nbsp;Dorothée Camus ,&nbsp;Anne Josseran ,&nbsp;Pascal Bécache ,&nbsp;Cécile Charle-Maachi ,&nbsp;Laure De Place ,&nbsp;Arthur Denninger ,&nbsp;Jérôme Fabiano ,&nbsp;Charlotte Gourio ,&nbsp;Vincent Vercamer","doi":"10.1016/j.therap.2023.10.005","DOIUrl":"10.1016/j.therap.2023.10.005","url":null,"abstract":"<div><p>Au début du 21^e siècle, de plus en plus, de dispositifs médicaux numériques (DMN) sont arrivés sur le marché européen apportant des bénéfices et des changements importants pour la société. Les DMN ont la particularité de diffuser de l’intelligence dans l’organisation des soins, de générer et recueillir de nombreuses données de vie réelle avec des cycles de vie ultra-rapides. Ils ont des exigences spécifiques notamment de sécurité de données et d’interopérabilité. En France et en Europe, la construction de preuves, le processus d’accès et les méthodologies d’évaluation en vue d’un achat ou d’un remboursement doivent s’adapter à ces changements compte tenu des particularités de ces technologiques. Cette avancée numérique a ouvert de nouvelles perspectives pour la santé, mais également des enjeux d’ordre économique, éthique et réglementaire. Le défi consiste à évaluer les impacts cliniques et organisationnels, la fiabilité, la sécurité, l’interopérabilité, l’efficience et l’impact budgétaire des DMN en cohérence avec les exigences des nouvelles normes, référentiels ou règlements. L’objectif étant de parvenir à une évaluation cohérente, pragmatique et proportionnée, permettant aux décideurs publics et acheteurs de capturer les opportunités potentielles que ces dispositifs numériques offrent pour améliorer les prestations de soins de santé. Ainsi, une évaluation juste et éclairée des DMN pourrait émerger, offrant une base solide pour guider leur intégration dans les pratiques médicales contemporaines. C’est cette problématique fondamentale d’évaluation liée à la nature numérique de ces DM que la table ronde, rassemblant des experts des milieux académiques et/ou hospitaliers, institutionnels et industriels, a entrepris de résoudre. Cette initiative a abouti à des discussions qui ont permis d’établir des propositions sur les modalités d’évaluation des DMN tenant compte de leur complexité. Cette démarche s’est attelée à établir les points de blocage sur l’ensemble du processus d’évaluation, depuis la phase de marquage CE, la conformité aux exigences françaises en matière de sécurité et interopérabilité jusqu’à l’évaluation nationale ou locale pour éclairer une politique d’achat afin de dresser des propositions sur l’ensemble du continuum. Ainsi, la table ronde a produit dix recommandations concrètes qui visent à améliorer l’évaluation en rendant le processus plus lisible et adaptable, offrant ainsi une flexibilité accrue dans les étapes d’évaluation et de prise de décision. Cette approche réfléchie s’efforce de promouvoir une évaluation approfondie et adaptative des DMN dans le contexte technologique en constante évolution.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136128325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can precision medicine be integrated into routine therapeutic decisions at the bedside of patients?","authors":"Florian Lemaitre ,&nbsp;Virginie Florentin ,&nbsp;Olivier Blin ,&nbsp;Arnaud Bayle ,&nbsp;Sylvain Benito ,&nbsp;Jean-Vannak Chauny ,&nbsp;Ariane Galaup ,&nbsp;Daria Korchagina ,&nbsp;Marie Lang ,&nbsp;Christophe Le Tourneau ,&nbsp;Hervé Pelloux ,&nbsp;Nicolas Picard ,&nbsp;Romain Guilhaumou","doi":"10.1016/j.therap.2023.11.007","DOIUrl":"10.1016/j.therap.2023.11.007","url":null,"abstract":"<div><p>Therapeutic strategies are shifting from a “one-size-fits-all” population-based approach to a stratified approach targeting groups with similar characteristics, or even individuals, tailoring treatments to the unique characteristics of each patient. Since such strategies rely on increasingly complex knowledge and healthcare technologies, along with an understanding of the tools of precision medicine, the appropriate dissemination and use of these strategies involves a number of challenges for the medical community. Having evaluation methodologies that have been jointly designed with the institutional, industrial, academic stakeholders, and also patients, like streamlining the processes and externally validating performances, could enhance the relevance of the “evaluation” aspect of precision medicine. Creating a network of expert precision-medicine centers and ensuring that precision-medicine procedures are reimbursed by social security would guarantee fair and sustainable access. Finally, training healthcare professionals, creating interfaces between precision-medicine expert centers and primary care professionals as well as patients, and integrating individual patient data into medical records are all key drivers that will enable information from precision-medicine to be made available and guarantee the proper use of these approaches.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138805453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Essais d’infection contrôlée chez la personne humaine : légitimité et conditions de réalisation en France","authors":"Anne-Laure Morin ,&nbsp;Emmanuelle Blanc ,&nbsp;Armelle Phalipon ,&nbsp;Pierre-Henri Bertoye ,&nbsp;Philippe Amiel ,&nbsp;Cécile Artaud ,&nbsp;Philippe Barthélemy ,&nbsp;Elisabeth Botelho-Nevers ,&nbsp;Soizic Courcier ,&nbsp;Jean-Luc Cracowski ,&nbsp;François Eisinger ,&nbsp;Remi Forrat ,&nbsp;Alina Gruber ,&nbsp;Euzebiusz Jamrozik ,&nbsp;Odile Launay ,&nbsp;Claire Le Jeunne ,&nbsp;David Simhon","doi":"10.1016/j.therap.2023.11.008","DOIUrl":"10.1016/j.therap.2023.11.008","url":null,"abstract":"<div><p>La présente table ronde est issue d’un constat : les essais cliniques d’infection contrôlée chez l’humain appelés également essais de « challenge infectieux » ou « <em>controlled human infection models</em> » ou « CHIM » recommandés voire encouragés dans le cadre, notamment- de développements vaccinaux, ne sont pas pratiqués sur le territoire français. Or, il n’existe pas d’interdit formel au sein de la réglementation ou des principes éthiques, qui se réfèrent à l’évaluation préalable des risques et des bénéfices pour la personne et pour la société. Les participants à cette table ronde ont ainsi souhaité examiner, à travers le prisme de leurs disciplines respectives, la pertinence que présenterait la conduite de tels essais en France sur les plans scientifique et médical et, s’ils s’avéraient possible, imaginer les conditions de leur réalisation. Des recommandations ont ainsi été formulées sur (1) l’opportunité de leur conduite en France (2), les conditions de leur mise en œuvre sur les plans logistiques et réglementaires, et (3) leur acceptabilité sociale. Les recommandations auxquelles sont parvenues les participants à la Table Ronde sont présentées au fil de l’analyse.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138805835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What should be done to combat misinformation about health products?","authors":"Joëlle Micallef ,&nbsp;Hervé Maisonneuve ,&nbsp;Sophie Muller ,&nbsp;Mathieu Molimard ,&nbsp;Bernard Bégaud ,&nbsp;Sandrine Cabut ,&nbsp;Mina Daban ,&nbsp;Milou-Daniel Drici ,&nbsp;Chantal Gatignol ,&nbsp;Anne Grumblat ,&nbsp;Catherine Guaspare-Cartron ,&nbsp;Bruno Lasserre ,&nbsp;Adel Mebarki ,&nbsp;Catherine Pons ,&nbsp;Frédérique Prabonnaud ,&nbsp;Catherine Raynaud ,&nbsp;Olivier Saint-Lary","doi":"10.1016/j.therap.2023.11.001","DOIUrl":"10.1016/j.therap.2023.11.001","url":null,"abstract":"<div><p>The increasing role of digital technology, social media, the wide range of channels and the volume of information, the role of medicine as a societal subject, public information that is insufficient and poorly suited to situations of uncertainty are all observations which led to the theme of this round table. After discussing the definition of disinformation, which is not limited to fake news, and talking about contributors who misinform, whether intentionally or not, the participants of this round table made nine recommendations (R) to combat disinformation about health products: create a collaborative platform, information/training on health products, a platform with five major characteristics, namely accessibility, flexibility, objectivity, transparency and independence, as well as media suited to the different targets (R1); promote basic knowledge on health products: education/training to restore the particularly poor image of medication, and teach the public how to use basic concepts appropriately (R2); improve communication to the public based on the observation that information is the main weapon against misinformation and entails, in particular, coordinating communication from the different institutions to make public information more audible, making institutional messages clearer, ensuring they are more factual and prioritising them (R3); know how to communicate using the correct codes and tools (R4), because, to be understood, the substance and the form are inseparable; develop research on communication in the field of health products (R5); acquire tools to identify and regulate as soon as possible (R6); keep check of content by developing critical thinking (R7); define quality criteria for information sources (R8); identify, assess and reference initiatives for the public that could be placed on the platform (R9).</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135566745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment faire entrer la médecine de précision dans la décision thérapeutique de routine au lit du malade ?","authors":"Florian Lemaitre ,&nbsp;Virginie Florentin ,&nbsp;Olivier Blin ,&nbsp;Arnaud Bayle ,&nbsp;Sylvain Benito ,&nbsp;Jean-Vannak Chauny ,&nbsp;Ariane Galaup ,&nbsp;Daria Korchagina ,&nbsp;Marie Lang ,&nbsp;Christophe Le Tourneau ,&nbsp;Hervé Pelloux ,&nbsp;Nicolas Picard ,&nbsp;Romain Guilhaumou","doi":"10.1016/j.therap.2023.10.014","DOIUrl":"10.1016/j.therap.2023.10.014","url":null,"abstract":"<div><p>Les stratégies thérapeutiques évoluent d’une approche populationnelle « <em>one size fits all</em> » vers une approche stratifiée, où des groupes présentant des caractéristiques homogènes sont ciblés, voire à l’échelle de l’individu où la thérapeutique est adaptée aux caractéristiques uniques du patient. Ces stratégies reposent sur des connaissances et des technologies de santé toujours plus complexes et la maîtrise des outils de cette médecine dite de précision, sa diffusion et son usage de manière adaptée posent un certain nombre de challenges pour la communauté médicale. Une co-construction des méthodologies d’évaluations avec les différents acteurs institutionnels, industriels, académiques ainsi que les patients et une fluidification de ces processus et la validation externe de la performance de ces approches pourraient renforcer la pertinence du volet « évaluation » de la médecine de précision. La création d’une structuration de centres experts de médecine de précision et de véritables actes de médecine de précision pris en charge par la sécurité sociale sont des propositions pour assurer l’accès équitable et pérenne à ces stratégies. Enfin, former les professionnels de santé, créer des interfaces entre les centres experts de médecine de précision et les professionnels de premiers recours ainsi que les patients, intégrer les données individuelles du patient dans son dossier médical sont les leviers permettant une mise à disposition des informations relatives à la médecine de précision et le bon usage de ces approches.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135615729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment prendre en compte la dimension éco-responsable des produits de santé tout au long de leur cycle de vie?","authors":"Bruno Laviolle ,&nbsp;Pierre-Frédéric Degon ,&nbsp;Cécile Gillet-Giraud ,&nbsp;Dominique Thiveaud ,&nbsp;Philippe Lechat ,&nbsp;Vera Boïko-Alaux ,&nbsp;Claire Fougerou ,&nbsp;Clara Jolly ,&nbsp;Abir Petit ,&nbsp;Isabelle Rémy-Jouet ,&nbsp;Raphaël Yven ,&nbsp;Laurence Bouret ,&nbsp;Laurie Marrauld ,&nbsp;Marie-Pierre Vaslet ,&nbsp;Virginie Delay ,&nbsp;Anne-Laure Gavory ,&nbsp;Florence Olle ,&nbsp;Julie Langevin ,&nbsp;Louise Forteau","doi":"10.1016/j.therap.2023.10.012","DOIUrl":"10.1016/j.therap.2023.10.012","url":null,"abstract":"<div><p>L’achat de produits de santé représente environ 50 % des émissions de gaz à effet de serre du système de santé français. Cet enseignement tiré de la publication des travaux du Shift Project en novembre 2021 a été un élément déclencheur au sein du système de santé, accélérant les réflexions et mises en œuvre d’actions visant à réduire les impacts environnementaux du système de santé, avant, pendant et après les soins. Au-delà de l’empreinte carbone, les impacts environnementaux des produits de santé sont divers : eau, air, sols…et ce tout au long de la vie des produits. Nous avons choisi de diviser ce cycle de vie en quatre étapes principales : la recherche et développement et la production; la distribution et l’accès au marché; l’usage; et enfin la gestion de la fin de vie. L’analyse du cadre règlementaire à chaque étape et les initiatives existantes, décrites dans la littérature ou par des acteurs de terrain ont structuré et nourri notre réflexion. Nous avons constaté que la règlementation existante conduit à une lecture exclusivement centrée sur le risque sanitaire, avec peu ou pas de prise en compte du risque environnemental, qui constitue pourtant en lui-même un risque pour la santé. Par ailleurs, la mise en œuvre de certaines actions structurantes au cours des 3 premières étapes du cycle de vie permettrait de simplifier, voire de supprimer la problématique aujourd’hui majeure de la gestion des déchets liée à la fin de vie des produits de santé. C’est dans ce sens que nous produisons 9 recommandations permettant une meilleure prise en compte des impacts environnementaux tout au long de la vie des produits de santé.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135410318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Controlled human infection trials: Legitimacy and conditions of implementation in France","authors":"Anne-Laure Morin ,&nbsp;Emmanuelle Blanc ,&nbsp;Armelle Phalipon ,&nbsp;Pierre-Henri Bertoye ,&nbsp;Philippe Amiel ,&nbsp;Cécile Artaud ,&nbsp;Philippe Barthélemy ,&nbsp;Elisabeth Botelho-Nevers ,&nbsp;Soizic Courcier ,&nbsp;Jean-Luc Cracowski ,&nbsp;François Eisinger ,&nbsp;Remi Forrat ,&nbsp;Alina Gruber ,&nbsp;Euzebiusz Jamrozik ,&nbsp;Odile Launay ,&nbsp;Claire Le Jeunne ,&nbsp;David Simhon","doi":"10.1016/j.therap.2023.11.009","DOIUrl":"10.1016/j.therap.2023.11.009","url":null,"abstract":"<div><p>This round table is the result of an observation. The observation being that controlled human infection clinical trials (also called “infectious challenge” trials or “Controlled Human Infection Models”, “CHIM”) recommended or even encouraged in the context of vaccine developments in particular, are not carried out in France. However, there are no formal prohibitions within regulations or ethical principles, which point to the prior assessment of risks and benefits for individuals and for society. The participants in this Round Table thus wished to examine, through the prism of their respective disciplines, the scientific and medical relevance of conducting such trials in France and, if possible, to imagine the conditions under which they would be carried out, thus resulting in recommendations on (1) the advisability of their conduct in France (2), the conditions under which they would be implemented in terms of logistics and regulations, and (3) their social acceptability. The recommendations on which the participants of the Round Table came to an agreement are presented as the analysis progresses.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138805537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Christmas adverse event syndrome: An analysis of the WHO pharmacovigilance database.","authors":"Alex Hlavaty, Matthieu Roustit, Marc Manceau, Jean-Luc Cracowski, Charles Khouri","doi":"10.1016/j.therap.2023.11.004","DOIUrl":"https://doi.org/10.1016/j.therap.2023.11.004","url":null,"abstract":"<p><strong>Objectives: </strong>We hypothesized that during the Christmas season the safety profile and the toxicity of some drugs may be exacerbated. We therefore assessed and characterized changes in drug safety profiles over the Christmas period.</p><p><strong>Design: </strong>We performed a retrospective longitudinal analysis of adverse events reported in the World Health Organization (WHO) pharmacovigilance database between April 1st 2017 to March 31th 2023.</p><p><strong>Setting: </strong>We extracted cases reported by the 5 main contributors' countries of the WHO pharmacovigilance database with a Christmas tradition: USA, France, Germany, Italy and UK.</p><p><strong>Participants: </strong>We analyzed 4,999,459 individual case safety reports from USA (n=3,498,961), France (n=419,018), Germany (n=398,763), Italy (n=251,641) and UK (n=431,076), reported between April 1st 2017 to March 31th 2023.</p><p><strong>Main outcome measures: </strong>Monthly reports of adverse events were analyzed. Time trend, seasonal effect a Christmas effect (December-January) were explored.</p><p><strong>Results: </strong>We found 91 adverse events significantly more frequently reported during the Christmas period, independently after controlling for winter effect and general tendency. The main type of adverse events were psychiatric disorders, infections and skin and subcutaneous disorders. The highest numbers of attributable cases to Christmas were found for drug dependence, emotional distress, and drug withdrawal syndrome. The most involved drugs were oxycodone in psychiatric disorders (n=47,527), docetaxel in skin disorders (n=9440) and social circumstances (n=1940), olmesartan in gastrointestinal disorders (n=1263), fentanyl in cardiac disorders (n=929), adalimumab in infections (n=11,316) and immune system disorders (n=3781), and collagenase clostridium histolyticum in reproductive system disorders (n=318).</p><p><strong>Conclusions: </strong>Our study shows that a range of drugs adverse events are more frequently reported at Christmas compared to other periods of the year, notably psychiatric disorders, infections, and skin disorders.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral facial palsy post SARS-CoV-2 vaccine: A regional pharmacovigilance cases series","authors":"Morgane Chamboux,&nbsp;Corinne Simon,&nbsp;Frédérique Beau-Salinas,&nbsp;Anaïs Maurier,&nbsp;Marie Sara Agier,&nbsp;Eve Marie Thillard,&nbsp;Bérenger Largeau,&nbsp;Annie Pierre Jonville-Bera","doi":"10.1016/j.therap.2023.02.005","DOIUrl":"10.1016/j.therap.2023.02.005","url":null,"abstract":"<div><p>Peripheral facial palsy (PFP) is a rare adverse reaction identified from clinical trials of coronavirus disease 2019 (COVID-19) vaccines (messenger ribonucleic acid [mRNA] and viral vector). Few data are available on their onset patterns and risk of recurrence after re-injection of a COVID-19 vaccine; the objective of this study was to describe PFP cases attributed to COVID-19 vaccines. All cases of facial paralysis reported to the Regional Pharmacovigilance Center of Centre-Val de Loire area between January and October 2021, in which the role of a COVID-19 vaccine was suspected, were selected. Based on initial data and following additional information requested, each case was reviewed and analyzed to include only confirmed cases of PFP for which the role of the vaccine could be retained. From the 38 cases reported, 23 were included (15 excluded because of diagnosis not retained). They occurred in 12 men and 11 women (median age of 51 years). The first clinical manifestations occurred with a median time of 9 days after COVID-19 vaccine injection, and the paralysis was homolateral to the vaccinated arm in 70%. The etiological workup, always negative, included brain imaging (48%), infectious serologies (74%) and Covid-19 PCR (52%). Corticosteroid therapy was prescribed for 20 (87%) patients, combined with aciclovir in 12 (52%). At 4-month follow-up, clinical manifestations had regressed completely or partially in 20 (87%) of the 23 patients (median time of 30 days). From them 12 (60%) received another dose of COVID-19 vaccine and none had a recurrence and the PFP regressed despite the second dose in 2 of the 3 patients not fully recovered at 4 months. The potential mechanism of PFP after COVID-19 vaccine, which don’t have a specific profile, is probably the interferon-γ. Moreover, the risk of recurrence after a new injection appears to be very low, which makes it possible to continue the vaccination.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9383776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in use of benzodiazepines and Z-drugs in France from 2012 to 2020","authors":"Anne Bénard-Laribière ,&nbsp;Elodie Pambrun ,&nbsp;Papa-Yatma Diop ,&nbsp;Antoine Pariente","doi":"10.1016/j.therap.2022.12.005","DOIUrl":"10.1016/j.therap.2022.12.005","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10454761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}